Financials data is unavailable for this security.
View more
Year on year Supriya Lifescience Ltd grew revenues 23.74% from 4.61bn to 5.70bn while net income improved 32.56% from 898.57m to 1.19bn.
Gross margin | 62.75% |
---|---|
Net profit margin | 22.58% |
Operating margin | 29.18% |
Return on assets | -- |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Supriya Lifescience Ltd fell by 826.26m. However, the company earned 1.13bn from its operations for a Cash Flow Margin of 19.87%. In addition the company used 1.74bn on investing activities and also paid 223.59m in financing cash flows.
Cash flow per share | 18.86 |
---|---|
Price/Cash flow per share | 32.31 |
Book value per share | -- |
---|---|
Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
Current ratio | -- |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 33.33% and 32.56%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg) | 0.14% |
---|---|
Div growth rate (5 year) | -- |
Payout ratio (TTM) | 4.76% |
EPS growth(5 years) | 24.75 |
---|---|
EPS (TTM) vs TTM 1 year ago | 45.07 |
More ▼